ACTRN12606000090516已完成3 期
A randomized phase III study to compare the effects of low-molecular weight heparin and unfractionated heparin in the prevention of proximal deep vein thrombosis in a critically ill population
适应症
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 3,650
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomised controlled trial
- 主要目的
- Prevention
- 盲法
- Blinded (masking used)
入排标准
- 年龄范围
- 18 Years 至 ot stated（—）
- 性别
- All
入选标准
- •Actual body weight >45 kgAdmission to ICU expected to be >72 hours durationEligible for either UFH or LWMH thromboprophylaxis.
排除标准
- •Contraindication to prophylactic heparinNeurosurgery within last 3 monthsIschemic or hemorrhagic stroke within last 3 monthsIntracranial hemorrhage, within last 3 monthsSystolic blood pressure (SBP) > 180 mmHg, diastolic blood pressure > 110 mmHg for > 12 hours requiring vasoactive drug infusionMajor hemorrhage within the last week unless definitively treated (e.g., AAA repair)Coagulopathy (INR > 2 x ULN, or PTT > 2 x ULN)Thrombocytopenia (platelet count < 75 x 109/L)Other heparin contraindications (e.g., HIT, pregnancy)Contraindications to blood products (e.g., Jehovah’s Witness)Unable to perform lower limb ultrasound (e.g., severe distal extremity burns)Limitation of life support (life expectancy < 7 days, or palliative care Contamination (e.g., > 3 days of any UFH or LMWH prophylaxis during this ICU admission).
研究者
相似试验
尚未招募
不适用
Tauranga Older Persons Comprehensive Assessment TrialACTRN12606000042549Ministry of Health, New Zealand320
招募中
1 期
A study to compare nemtabrutinib to standard cancer treatments in people with untreated blood cancerChronic lymphocytic leukemia/ small lymphocytic lymphomaMedDRA version: 21.1Level: LLTClassification code: 10003910Term: B-cell small lymphocytic lymphoma NOS Class: 10029104MedDRA version: 21.0Level: LLTClassification code: 10008976Term: Chronic lymphocytic leukemia Class: 10029104CTIS2022-501481-21-00Merck Sharp & Dohme LLC212
招募中
3 期
Early inpatient-outpatient hospital-based pulmonary rehabilitation following hospitalisation for acute exacerbations of COPD: a randomised controlled studyChronic Obstructive Pulmonary Disease (COPD)Respiratory - Chronic obstructive pulmonary diseasePhysical Medicine / Rehabilitation - Other physical medicine / rehabilitationACTRN12605000372684Green Lane Research and Educational Fund100
进行中（未招募）
1 期
A Phase 3, Randomized Study to Evaluate the Efficacy and Safety of Lenvatinib (E7080/MK-7902) plus Pembrolizumab (MK-3475) plus Chemotherapy Compared with Standard of Care Therapy as First-line Intervention in Participants with Advanced/Metastatic Gastroesophageal Adenocarcinoma (LEAP-015)ocally advanced unresectable/metastatic gastroesophageal adenocarcinomaMedDRA version: 21.1Level: LLTClassification code 10071114Term: Metastatic gastric adenocarcinomaSystem Organ Class: 100000004864EUCTR2020-001990-53-DEMerck Sharp & Dohme LLC878
进行中（未招募）
1 期
A Phase 3, Randomized Study to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) + Lenvatinib (E7080/MK-7902) + Chemotherapy Compared with Standard of Care as First-line Intervention in Participants with Metastatic Esophageal CarcinomaMetastatic squamous cell carcinoma of the esophagusMedDRA version: 21.0Level: LLTClassification code 10041824Term: Squamous cell carcinoma of esophagusSystem Organ Class: 100000004864EUCTR2020-001911-26-ITMERCK SHARP & DOHME CORP. UNA SUSSIDIARIA DI MERCK & CO. INC.862